Data from a phase I study of the safety and clinical activity of the anti-PD-L1 monoclonal antibody atezolizumab in patients with metastatic renal cell carcinoma (mRCC) indicate that atezolizumab is well tolerated: only 17% of patients had any adverse events, of which, only 4% had immune-mediated events of grade ≤3. No grade 4 or 5 adverse events were reported. 22% of patients had an objective response to treatment, and patients had a median overall survival of 28.9 months. These data indicate a need for further testing of atezolizumab in patients with mRCC.
References
McDermott, D. F. et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.63.7421 (2016)
Rights and permissions
About this article
Cite this article
Sidaway, P. Atezolizumab: well-tolerated for mRCC. Nat Rev Urol 13, 125 (2016). https://doi.org/10.1038/nrurol.2016.18
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.18